Thrombate III (antithrombin III human) / Grifols - LARVOL DELTA

Antithrombin testing and treatment in pregnancy: Their real-world relationship to clinical outcomes. (PubMed, Thromb Res) - "Opportunities exist to enhance the care of pregnant individuals with low AT levels throughout pregnancy, aiming for optimal maternal outcomes."

Clinical data • Journal • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism

SAFETY AND COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULATION THERAPY IN ADULT PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION (THSNA 2024) - "Recent Extracorporeal Life Support Organization (ELSO) guidelines also recommend the use of direct thrombin inhibitors (DTIs), bivalirudin and argatroban, in patients with diagnosed heparin-induced thrombocytopenia (HIT) undergoing extracorporeal membrane oxygenation (ECMO)... Anticoagulation with DTIs in patients undergoing extracorporeal membrane oxygenation showed a statistically significantly higher rate of thrombosis and a longer median length of stay compared to treatment with AT3. No difference in cost and bleed events were identified. Further studies are needed to validate the clinical and economic differences between these two therapies for anticoagulation in ECMO."

Clinical • Cost effectiveness • HEOR • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Predictive Value of Antithrombin III and d-Dimer in the Development of Moderate-To-Severe Acute Pancreatitis: A Prospective, Observational Study (AT-PROPANC). (PubMed, Pancreas) - P=N/A | "Low AT-III and high d -dimer plasma levels at 24 hours after admission were significantly associated with MSAP/SAP, although their predictive ability was low. C-reactive protein was the best marker tested."

Journal • Observational data • Infectious Disease • Pancreatitis • CRP

Antithrombin III in Infectious Disease Caused by COVID-19 (clinicaltrials.gov) - P2 | N=52 | Terminated | Sponsor: Enrique Ginzburg | N=75 ➔ 52 | Trial completion date: Jul 2022 ➔ Mar 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2022 ➔ Mar 2022; There are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep our cohort homogenous.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

PiVoT: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Jonathan Stine | N=40 ➔ 0 | Trial completion date: Jun 2023 ➔ Feb 2022 | Recruiting ➔ Withdrawn | Trial primary completion date: Dec 2022 ➔ Feb 2022

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Immunology • Liver Cirrhosis • Thrombosis • Venous Thromboembolism

Antithrombin III in Infectious Disease Caused by COVID-19 (clinicaltrials.gov) - P2; N=75; Recruiting; Sponsor: Enrique Ginzburg; Trial completion date: Dec 2021 ➔ Jul 2022; Trial primary completion date: Dec 2021 ➔ Jun 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Antithrombin III in Infectious Disease Caused by COVID-19 (clinicaltrials.gov) - P2; N=75; Recruiting; Sponsor: Enrique Ginzburg; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

PiVoT: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Jonathan Stine; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Immunology • Liver Cirrhosis • Thrombosis • Venous Thromboembolism

Antithrombin III in Infectious Disease Caused by COVID-19 (clinicaltrials.gov) - P2; N=75; Not yet recruiting; Sponsor: Enrique Ginzburg

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

PiVoT: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Jonathan Stine; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Immunology • Liver Cirrhosis • Thrombosis • Venous Thromboembolism

[VIRTUAL] Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device (ASH 2020) - "Similarly, RBC adhesion significantly increased in thrombin-treated microchannels, and could be similarly mitigated by pre-treatment of the endothelium with AT-III. Taken together, our in vitro model suggests that AT-III may be worthy of investigation as a treatment for SCD associated thromboinflammation and vaso-occlusive crises."

Genetic Disorders • Hematological Disorders • Immunology • Inflammation • Sickle Cell Disease

PiVoT: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Jonathan Stine; Initiation date: Mar 2020 ➔ Jul 2020

Clinical • Trial initiation date • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Immunology • Non-alcoholic Fatty Liver Disease • Thrombosis • Venous Thromboembolism

PiVoT: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Jonathan Stine

Clinical • New P1 trial

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Children's Hospital Medical Center, Cincinnati; Recruiting ➔ Completed; N=42 ➔ 27; Trial completion date: Jun 2017 ➔ Jun 2018; Trial primary completion date: Jun 2017 ➔ Jun 2018

Enrollment change • Trial completion • Trial completion date • Trial primary completion date